Ibba Luciano, Gargiulo Luigi, Pavia Giulia, Narcisi Alessandra, Costanzo Antonio, Valenti Mario
Department of Biomedical Sciences, Humanitas University, Pieve Emanuele.
Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, Italy.
Dermatol Reports. 2023 Jun 6;16(1):9722. doi: 10.4081/dr.2023.9722. eCollection 2024 Mar 12.
The development of flares or new-onset of immune-mediated dermatologic diseases, including psoriasis, has occurred with the worldwide spreading of the COVID-19 pandemic. We report the case of a 38-year-old woman who came to our department with a severe flare of plaque psoriasis four weeks after SARS-CoV-2 infection. Her Psoriasis Area Severity Index was 25, and her Dermatology Life Quality Index was 18. Our initial decision was to prescribe acitretin, but the patients reported adverse events. For this reason, we started risankizumab with complete skin clearance after 16 weeks. The patient is still on treatment, and no adverse events have been reported to date.
随着新冠疫情在全球范围内的蔓延，出现了皮疹或免疫介导的皮肤病（包括银屑病）新发的情况。我们报告了一例38岁女性病例，该患者在感染SARS-CoV-2四周后因斑块状银屑病严重发作前来我院就诊。她的银屑病面积和严重程度指数为25，皮肤病生活质量指数为18。我们最初决定开具阿维A，但患者报告了不良事件。因此，我们开始使用司库奇尤单抗，16周后皮肤完全清除。该患者仍在接受治疗，迄今为止未报告不良事件。
